CD47 Blocker ALX148 Safe to Combine With Antibody Regimens, Chemotherapy in Gastric/GEJ and HNSCC
November 13th 2020
November 13, 2020 - ALX148 showcased favorable safety and elicited objective responses when combined with trastuzumab, pembrolizumab, and multiagent chemotherapy regimens in patients with gastric/gastroesophageal junction cancer and head and neck squamous cell carcinoma.